Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 148

1.

CaMKK2 in myeloid cells is a key regulator of the immune-suppressive microenvironment in breast cancer.

Racioppi L, Nelson ER, Huang W, Mukherjee D, Lawrence SA, Lento W, Masci AM, Jiao Y, Park S, York B, Liu Y, Baek AE, Drewry DH, Zuercher WJ, Bertani FR, Businaro L, Geradts J, Hall A, Means AR, Chao N, Chang CY, McDonnell DP.

Nat Commun. 2019 Jun 4;10(1):2450. doi: 10.1038/s41467-019-10424-5.

2.

Expression of tetraspanins NET-6 and CD151 in breast cancer as a potential tumor biomarker.

Jiang L, Zhang X, Geradts J, Wei Q, Hochwald S, Xu H, Huang H.

Clin Exp Med. 2019 Apr 20. doi: 10.1007/s10238-019-00554-x. [Epub ahead of print]

PMID:
31004251
3.

Deletion of the p16INK4a tumor suppressor and expression of the androgen receptor induce sarcomatoid carcinomas with signet ring cells in the mouse prostate.

Lee DH, Yu EJ, Aldahl J, Yang J, He Y, Hooker E, Le V, Mi J, Olson A, Wu H, Geradts J, Xiao GQ, Gonzalgo ML, Cardiff RD, Sun Z.

PLoS One. 2019 Jan 24;14(1):e0211153. doi: 10.1371/journal.pone.0211153. eCollection 2019.

4.

Differences in race, molecular and tumor characteristics among women diagnosed with invasive ductal and lobular breast carcinomas.

Williams LA, Hoadley KA, Nichols HB, Geradts J, Perou CM, Love MI, Olshan AF, Troester MA.

Cancer Causes Control. 2019 Jan;30(1):31-39. doi: 10.1007/s10552-018-1121-1. Epub 2019 Jan 8.

5.

Image analysis with deep learning to predict breast cancer grade, ER status, histologic subtype, and intrinsic subtype.

Couture HD, Williams LA, Geradts J, Nyante SJ, Butler EN, Marron JS, Perou CM, Troester MA, Niethammer M.

NPJ Breast Cancer. 2018 Sep 3;4:30. doi: 10.1038/s41523-018-0079-1. eCollection 2018.

6.

Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial.

Paoletti C, Schiavon G, Dolce EM, Darga EP, Carr TH, Geradts J, Hoch M, Klinowska T, Lindemann J, Marshall G, Morgan S, Patel P, Rowlands V, Sathiyayogan N, Aung K, Hamilton E, Patel M, Armstrong A, Jhaveri K, Im SA, Iqbal N, Butt F, Dive C, Harrington EA, Barrett JC, Baird R, Hayes DF.

Clin Cancer Res. 2018 Dec 1;24(23):5860-5872. doi: 10.1158/1078-0432.CCR-18-1569. Epub 2018 Aug 6.

PMID:
30082476
7.

Estrogen-regulated feedback loop limits the efficacy of estrogen receptor-targeted breast cancer therapy.

Xiao T, Li W, Wang X, Xu H, Yang J, Wu Q, Huang Y, Geradts J, Jiang P, Fei T, Chi D, Zang C, Liao Q, Rennhack J, Andrechek E, Li N, Detre S, Dowsett M, Jeselsohn RM, Liu XS, Brown M.

Proc Natl Acad Sci U S A. 2018 Jul 31;115(31):7869-7878. doi: 10.1073/pnas.1722617115. Epub 2018 Jul 9.

8.

TP53 protein levels, RNA-based pathway assessment, and race among invasive breast cancer cases.

Williams LA, Butler EN, Sun X, Allott EH, Cohen SM, Fuller AM, Hoadley KA, Perou CM, Geradts J, Olshan AF, Troester MA.

NPJ Breast Cancer. 2018 Jun 25;4:13. doi: 10.1038/s41523-018-0067-5. eCollection 2018.

9.

Differential cellular localization of CELSR2 and ING4 and correlations with hormone receptor status in breast cancer.

Jiang L, Zhang X, Xiang C, Geradts J, Wei Q, Liang Y, Huang H, Xu JF.

Histol Histopathol. 2018 Aug;33(8):835-842. doi: 10.14670/HH-11-979. Epub 2018 Feb 28.

PMID:
29489009
10.

Frequency of breast cancer subtypes among African American women in the AMBER consortium.

Allott EH, Geradts J, Cohen SM, Khoury T, Zirpoli GR, Bshara W, Davis W, Omilian A, Nair P, Ondracek RP, Cheng TD, Miller CR, Hwang H, Thorne LB, O'Connor S, Bethea TN, Bell ME, Hu Z, Li Y, Kirk EL, Sun X, Ruiz-Narvaez EA, Perou CM, Palmer JR, Olshan AF, Ambrosone CB, Troester MA.

Breast Cancer Res. 2018 Feb 6;20(1):12. doi: 10.1186/s13058-018-0939-5.

11.

XIAP Regulation by MNK Links MAPK and NFκB Signaling to Determine an Aggressive Breast Cancer Phenotype.

Evans MK, Brown MC, Geradts J, Bao X, Robinson TJ, Jolly MK, Vermeulen PB, Palmer GM, Gromeier M, Levine H, Morse MA, Van Laere SJ, Devi GR.

Cancer Res. 2018 Apr 1;78(7):1726-1738. doi: 10.1158/0008-5472.CAN-17-1667. Epub 2018 Jan 19.

12.

Prediagnostic Smoking Is Associated with Binary and Quantitative Measures of ER Protein and ESR1 mRNA Expression in Breast Tumors.

Butler EN, Bensen JT, Chen M, Conway K, Richardson DB, Sun X, Geradts J, Olshan AF, Troester MA.

Cancer Epidemiol Biomarkers Prev. 2018 Jan;27(1):67-74. doi: 10.1158/1055-9965.EPI-17-0404. Epub 2017 Nov 13.

13.

Reproductive risk factor associations with lobular and ductal carcinoma in the Carolina Breast Cancer Study.

Williams LA, Nichols HB, Hoadley KA, Tse CK, Geradts J, Bell ME, Perou CM, Love MI, Olshan AF, Troester MA.

Cancer Causes Control. 2018 Jan;29(1):25-32. doi: 10.1007/s10552-017-0977-9. Epub 2017 Nov 9.

14.

Ki-67 Expression in Breast Cancer Tissue Microarrays: Assessing Tumor Heterogeneity, Concordance With Full Section, and Scoring Methods.

Khoury T, Zirpoli G, Cohen SM, Geradts J, Omilian A, Davis W, Bshara W, Miller R, Mathews MM, Troester M, Palmer JR, Ambrosone CB.

Am J Clin Pathol. 2017 Aug 1;148(2):108-118. doi: 10.1093/ajcp/aqx053.

15.

Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study.

Troester MA, Sun X, Allott EH, Geradts J, Cohen SM, Tse CK, Kirk EL, Thorne LB, Mathews M, Li Y, Hu Z, Robinson WR, Hoadley KA, Olopade OI, Reeder-Hayes KE, Earp HS, Olshan AF, Carey LA, Perou CM.

J Natl Cancer Inst. 2018 Feb 1;110(2). doi: 10.1093/jnci/djx135.

16.

Prostate-derived Ets factor, an oncogenic driver in breast cancer.

Sood AK, Geradts J, Young J.

Tumour Biol. 2017 May;39(5):1010428317691688. doi: 10.1177/1010428317691688. Review.

PMID:
28468594
17.

Miniature spectral imaging device for wide-field quantitative functional imaging of the morphological landscape of breast tumor margins.

Nichols BS, Llopis A, Palmer GM, McCachren SS 3rd, Senlik O, Miller D, Brooke MA, Jokerst NM, Geradts J, Greenup R, Ramanujam N.

J Biomed Opt. 2017 Feb 1;22(2):26007. doi: 10.1117/1.JBO.22.2.026007.

18.

CYP27A1 Loss Dysregulates Cholesterol Homeostasis in Prostate Cancer.

Alfaqih MA, Nelson ER, Liu W, Safi R, Jasper JS, Macias E, Geradts J, Thompson JW, Dubois LG, Freeman MR, Chang CY, Chi JT, McDonnell DP, Freedland SJ.

Cancer Res. 2017 Apr 1;77(7):1662-1673. doi: 10.1158/0008-5472.CAN-16-2738. Epub 2017 Jan 27.

19.

Intratumoral heterogeneity as a source of discordance in breast cancer biomarker classification.

Allott EH, Geradts J, Sun X, Cohen SM, Zirpoli GR, Khoury T, Bshara W, Chen M, Sherman ME, Palmer JR, Ambrosone CB, Olshan AF, Troester MA.

Breast Cancer Res. 2016 Jun 28;18(1):68. doi: 10.1186/s13058-016-0725-1.

20.

Correlation of breast tissue histology and optical signatures to improve margin assessment techniques.

Kennedy S, Caldwell M, Bydlon T, Mulvey C, Mueller J, Wilke L, Barry W, Ramanujam N, Geradts J.

J Biomed Opt. 2016 Jun 1;21(6):66014. doi: 10.1117/1.JBO.21.6.066014.

21.

Validation of an oligo-gene signature for the prognostic stratification of ductal carcinoma in situ (DCIS).

Geradts J, Groth J, Wu Y, Jin G.

Breast Cancer Res Treat. 2016 Jun;157(3):447-59. doi: 10.1007/s10549-016-3838-4. Epub 2016 Jun 1.

PMID:
27250000
22.

Rapid staining and imaging of subnuclear features to differentiate between malignant and benign breast tissues at a point-of-care setting.

Mueller JL, Gallagher JE, Chitalia R, Krieger M, Erkanli A, Willett RM, Geradts J, Ramanujam N.

J Cancer Res Clin Oncol. 2016 Jul;142(7):1475-86. doi: 10.1007/s00432-016-2165-9. Epub 2016 Apr 22.

23.

Inverse association between MDM2 and HUWE1 protein expression levels in human breast cancer and liposarcoma.

Canfield K, Wells W, Geradts J, Kinlaw WB, Cheng C, Kurokawa M.

Int J Clin Exp Pathol. 2016;9(6):6342-6349. Epub 2016 Jun 15.

24.

Performance of Three-Biomarker Immunohistochemistry for Intrinsic Breast Cancer Subtyping in the AMBER Consortium.

Allott EH, Cohen SM, Geradts J, Sun X, Khoury T, Bshara W, Zirpoli GR, Miller CR, Hwang H, Thorne LB, O'Connor S, Tse CK, Bell MB, Hu Z, Li Y, Kirk EL, Bethea TN, Perou CM, Palmer JR, Ambrosone CB, Olshan AF, Troester MA.

Cancer Epidemiol Biomarkers Prev. 2016 Mar;25(3):470-8. doi: 10.1158/1055-9965.EPI-15-0874. Epub 2015 Dec 28.

25.

FAS Death Receptor: A Breast Cancer Subtype-Specific Radiation Response Biomarker and Potential Therapeutic Target.

Horton JK, Siamakpour-Reihani S, Lee CT, Zhou Y, Chen W, Geradts J, Fels DR, Hoang P, Ashcraft KA, Groth J, Kung HN, Dewhirst MW, Chi JT.

Radiat Res. 2015 Nov;184(5):456-69. doi: 10.1667/RR14089.1. Epub 2015 Oct 21.

26.

CHAMBER: A Regional Performance Improvement CME Initiative for Breast Cancer Health Care Providers.

Sutton LM, Geradts J, Hamilton EP, Havlin KA, Kimmick GG, Marcom PK, Spector NL, Watson M, Rabin DU, Bruno TO, Noe A, Miller S, Subramaniam C, Layton S, Grichnik K.

J Natl Compr Canc Netw. 2015 Aug;13(8):1005-11.

PMID:
26285246
27.

Rational Manual and Automated Scoring Thresholds for the Immunohistochemical Detection of TP53 Missense Mutations in Human Breast Carcinomas.

Taylor NJ, Nikolaishvili-Feinberg N, Midkiff BR, Conway K, Millikan RC, Geradts J.

Appl Immunohistochem Mol Morphol. 2016 Jul;24(6):398-404. doi: 10.1097/PAI.0000000000000207.

28.

Nuclear basic fibroblast growth factor regulates triple-negative breast cancer chemo-resistance.

Li S, Payne S, Wang F, Claus P, Su Z, Groth J, Geradts J, de Ridder G, Alvarez R, Marcom PK, Pizzo SV, Bachelder RE.

Breast Cancer Res. 2015 Jul 4;17:91. doi: 10.1186/s13058-015-0590-3.

29.

Preoperative Single-Fraction Partial Breast Radiation Therapy: A Novel Phase 1, Dose-Escalation Protocol With Radiation Response Biomarkers.

Horton JK, Blitzblau RC, Yoo S, Geradts J, Chang Z, Baker JA, Georgiade GS, Chen W, Siamakpour-Reihani S, Wang C, Broadwater G, Groth J, Palta M, Dewhirst M, Barry WT, Duffy EA, Chi JT, Hwang ES.

Int J Radiat Oncol Biol Phys. 2015 Jul 15;92(4):846-55. doi: 10.1016/j.ijrobp.2015.03.007. Epub 2015 Mar 14.

30.

A Quantitative Diffuse Reflectance Imaging (QDRI) System for Comprehensive Surveillance of the Morphological Landscape in Breast Tumor Margins.

Nichols BS, Schindler CE, Brown JQ, Wilke LG, Mulvey CS, Krieger MS, Gallagher J, Geradts J, Greenup RA, Von Windheim JA, Ramanujam N.

PLoS One. 2015 Jun 15;10(6):e0127525. doi: 10.1371/journal.pone.0127525. eCollection 2015.

31.

A quantitative microscopic approach to predict local recurrence based on in vivo intraoperative imaging of sarcoma tumor margins.

Mueller JL, Fu HL, Mito JK, Whitley MJ, Chitalia R, Erkanli A, Dodd L, Cardona DM, Geradts J, Willett RM, Kirsch DG, Ramanujam N.

Int J Cancer. 2015 Nov 15;137(10):2403-12. doi: 10.1002/ijc.29611. Epub 2015 Jun 3.

32.

Automated, quantitative analysis of histopathological staining in nuclei.

Henao R, Geradts J, Kurokawa M, Kornbluth S, Lucas JE.

AMIA Jt Summits Transl Sci Proc. 2014 Apr 7;2014:54-9. eCollection 2014.

33.

DNA methylation profiling in the Carolina Breast Cancer Study defines cancer subclasses differing in clinicopathologic characteristics and survival.

Conway K, Edmiston SN, May R, Kuan PF, Chu H, Bryant C, Tse CK, Swift-Scanlan T, Geradts J, Troester MA, Millikan RC.

Breast Cancer Res. 2014 Oct 7;16(5):450. doi: 10.1186/s13058-014-0450-6.

34.

A signature of epithelial-mesenchymal plasticity and stromal activation in primary tumor modulates late recurrence in breast cancer independent of disease subtype.

Cheng Q, Chang JT, Gwin WR, Zhu J, Ambs S, Geradts J, Lyerly HK.

Breast Cancer Res. 2014 Jul 25;16(4):407. doi: 10.1186/s13058-014-0407-9.

35.

27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology.

Nelson ER, Wardell SE, Jasper JS, Park S, Suchindran S, Howe MK, Carver NJ, Pillai RV, Sullivan PM, Sondhi V, Umetani M, Geradts J, McDonnell DP.

Science. 2013 Nov 29;342(6162):1094-8. doi: 10.1126/science.1241908.

36.

αB-crystallin: a novel regulator of breast cancer metastasis to the brain.

Malin D, Strekalova E, Petrovic V, Deal AM, Al Ahmad A, Adamo B, Miller CR, Ugolkov A, Livasy C, Fritchie K, Hamilton E, Blackwell K, Geradts J, Ewend M, Carey L, Shusta EV, Anders CK, Cryns VL.

Clin Cancer Res. 2014 Jan 1;20(1):56-67. doi: 10.1158/1078-0432.CCR-13-1255. Epub 2013 Oct 16.

37.

Optical spectral surveillance of breast tissue landscapes for detection of residual disease in breast tumor margins.

Brown JQ, Bydlon TM, Kennedy SA, Caldwell ML, Gallagher JE, Junker M, Wilke LG, Barry WT, Geradts J, Ramanujam N.

PLoS One. 2013 Jul 26;8(7):e69906. doi: 10.1371/journal.pone.0069906. Print 2013.

38.

Quantitative Segmentation of Fluorescence Microscopy Images of Heterogeneous Tissue: Application to the Detection of Residual Disease in Tumor Margins.

Mueller JL, Harmany ZT, Mito JK, Kennedy SA, Kim Y, Dodd L, Geradts J, Kirsch DG, Willett RM, Brown JQ, Ramanujam N.

PLoS One. 2013 Jun 18;8(6):e66198. doi: 10.1371/journal.pone.0066198. Print 2013.

39.

A network of substrates of the E3 ubiquitin ligases MDM2 and HUWE1 control apoptosis independently of p53.

Kurokawa M, Kim J, Geradts J, Matsuura K, Liu L, Ran X, Xia W, Ribar TJ, Henao R, Dewhirst MW, Kim WJ, Lucas JE, Wang S, Spector NL, Kornbluth S.

Sci Signal. 2013 May 7;6(274):ra32. doi: 10.1126/scisignal.2003741.

40.

Multidisciplinary care of patients with early-stage breast cancer.

Lyman GH, Baker J, Geradts J, Horton J, Kimmick G, Peppercorn J, Pruitt S, Scheri RP, Hwang ES.

Surg Oncol Clin N Am. 2013 Apr;22(2):299-317. doi: 10.1016/j.soc.2012.12.005. Epub 2013 Jan 3. Review.

PMID:
23453336
41.

Advancing optical imaging for breast margin assessment: an analysis of excisional time, cautery, and patent blue dye on underlying sources of contrast.

Bydlon TM, Barry WT, Kennedy SA, Brown JQ, Gallagher JE, Wilke LG, Geradts J, Ramanujam N.

PLoS One. 2012;7(12):e51418. doi: 10.1371/journal.pone.0051418. Epub 2012 Dec 10.

42.

Differential copy number aberrations in novel candidate genes associated with progression from in situ to invasive ductal carcinoma of the breast.

Liao S, Desouki MM, Gaile DP, Shepherd L, Nowak NJ, Conroy J, Barry WT, Geradts J.

Genes Chromosomes Cancer. 2012 Dec;51(12):1067-78. doi: 10.1002/gcc.21991. Epub 2012 Aug 9.

43.

Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer.

Cheng Q, Chang JT, Geradts J, Neckers LM, Haystead T, Spector NL, Lyerly HK.

Breast Cancer Res. 2012 Apr 17;14(2):R62.

44.

Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases.

Adamo B, Deal AM, Burrows E, Geradts J, Hamilton E, Blackwell KL, Livasy C, Fritchie K, Prat A, Harrell JC, Ewend MG, Carey LA, Miller CR, Anders CK.

Breast Cancer Res. 2011;13(6):R125. doi: 10.1186/bcr3071. Epub 2011 Dec 1.

45.

PDEF in prostate cancer.

Sood AK, Kim H, Geradts J.

Prostate. 2012 May 1;72(6):592-6. doi: 10.1002/pros.21461. Epub 2011 Jul 27. Review.

PMID:
21796651
46.

Upregulation of VEGF-A and CD24 gene expression by the tGLI1 transcription factor contributes to the aggressive behavior of breast cancer cells.

Cao X, Geradts J, Dewhirst MW, Lo HW.

Oncogene. 2012 Jan 5;31(1):104-15. doi: 10.1038/onc.2011.219. Epub 2011 Jun 13.

47.

Endobronchial metastatic breast cancer with pagetoid histology mimicking bronchial pagetoid squamous cell carcinoma in situ.

West D, Geradts J, Wahidi M, Roggli V.

Hum Pathol. 2011 Nov;42(11):1819-22. doi: 10.1016/j.humpath.2011.02.009. Epub 2011 Jun 12.

PMID:
21663936
48.

The genomic relationship between primary breast carcinomas and their nodal metastases.

Desouki MM, Liao S, Conroy J, Nowak NJ, Shepherd L, Gaile DP, Geradts J.

Cancer Invest. 2011 May;29(4):300-7. doi: 10.3109/07357907.2011.568564.

PMID:
21469979
49.

Nuclear Snail1 and nuclear ZEB1 protein expression in invasive and intraductal human breast carcinomas.

Geradts J, de Herreros AG, Su Z, Burchette J, Broadwater G, Bachelder RE.

Hum Pathol. 2011 Aug;42(8):1125-31. doi: 10.1016/j.humpath.2010.11.004. Epub 2011 Feb 11. Erratum in: Hum Pathol. 2012 Oct;43(10):1787.

50.

Protein microarray analysis of mammary epithelial cells from obese and nonobese women at high risk for breast cancer: feasibility data.

Pilie PG, Ibarra-Drendall C, Troch MM, Broadwater G, Barry WT, Petricoin EF 3rd, Wulfkuhle JD, Liotta LA, Lem S, Baker JC Jr, Stouder A, Ford AC, Wilke LG, Zalles CM, Mehta P, Williams J, Shivraj M, Su Z, Geradts J, Yu D, Seewaldt VL.

Cancer Epidemiol Biomarkers Prev. 2011 Mar;20(3):476-82. doi: 10.1158/1055-9965.EPI-10-0847. Epub 2011 Jan 17.

Supplemental Content

Loading ...
Support Center